{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:34:56Z","timestamp":1772166896794,"version":"3.50.1"},"reference-count":17,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Determining how quickly bisphosphonate treatment effects begin to regress is crucial when considering termination of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Our objective was to assess the effects of 1 yr discontinuation of risedronate use in postmenopausal women with osteoporosis who had previously received risedronate for 2 or 7 yr.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Setting:<\/jats:title>\n                    <jats:p>Before initiation of the current study, placebo\/5-mg-risedronate patients had received placebo for 5 yr and risedronate for 2 yr, whereas 5-mg-risedronate patients had received risedronate for a total of 7 yr. Risedronate was then discontinued for 1 yr (yr 8).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients:<\/jats:title>\n                    <jats:p>Postmenopausal women with osteoporosis who had previously completed the 3-yr Vertebral Efficacy with Risedronate Therapy MultiNational (VERT-MN) pivotal trial, plus a 2-yr extension comparing risedronate or placebo for a total of 5 yr, followed by 2 yr of open-label risedronate treatment were enrolled in these trial extensions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures:<\/jats:title>\n                    <jats:p>Evaluations included changes in type I collagen cross-linked N-telopeptide (NTX)\/creatinine (Cr) and bone mineral density (BMD) values, fracture incidence, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>After 1 yr of risedronate discontinuation, NTX\/Cr levels increased toward baseline in both patient groups vs. the values at the end of yr 7. In both treatment groups, off-treatment total hip and femoral trochanter BMD values decreased, whereas lumbar spine and femoral neck BMD were maintained or slightly increased. The adverse event profiles were similar between the two treatment groups during yr 8.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>One year of discontinuation of risedronate treatment in patients who had received 2 or 7 yr of risedronate therapy led to increases in NTX\/Cr levels toward baseline and decreases in femoral trochanter and total hip BMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2011-0412","type":"journal-article","created":{"date-parts":[[2011,8,24]],"date-time":"2011-08-24T23:34:08Z","timestamp":1314228848000},"page":"3367-3373","source":"Crossref","is-referenced-by-count":73,"title":["Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover"],"prefix":"10.1210","volume":"96","author":[{"given":"Richard","family":"Eastell","sequence":"first","affiliation":[{"name":"Academic Unit of Bone Metabolism (R.E., R.A.H.), University of Sheffield, Sheffield S5 7AU, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary A.","family":"Hannon","sequence":"additional","affiliation":[{"name":"Academic Unit of Bone Metabolism (R.E., R.A.H.), University of Sheffield, Sheffield S5 7AU, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Wenderoth","sequence":"additional","affiliation":[{"name":"Warner Chilcott Deutschland GmbH (D.W.), D-64331 Weiterstadt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Rodriguez-Moreno","sequence":"additional","affiliation":[{"name":"Service of Rheumatology (J.R.-M.), Hospital Universitari de Bellvitge, ES-8907 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Sawicki","sequence":"additional","affiliation":[{"name":"Centrum Medyczne Osteomed (A.S.), 02-256 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071617571706800_B1","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"2020071617571706800_B2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women.","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"2020071617571706800_B3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial Long-term Extension.","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071617571706800_B4","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.103","article-title":"Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.","volume":"25","author":"Grey","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2020071617571706800_B5","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1210\/jcem.80.12.8530584","article-title":"Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate.","volume":"80","author":"Landman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617571706800_B6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2265.1997.d01-1741.x","article-title":"Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis","volume":"46","author":"Orr-Walker","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617571706800_B7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate.","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"key":"2020071617571706800_B8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"2020071617571706800_B9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience.","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"2020071617571706800_B10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis.","volume":"75","author":"Mellstr\u00f6m","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"2020071617571706800_B11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"2020071617571706800_B12","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.","volume":"93","author":"Miller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617571706800_B13","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.bone.2010.01.045","article-title":"Re-initiation of risedronate 5 mg daily therapy in patients on long-term treatment after 1-year of discontinuation: effects at 9 and 10 years.","volume":"46","author":"Eastell","year":"2010","journal-title":"Bone"},{"key":"2020071617571706800_B14","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2020071617571706800_B15","first-page":"A09002360","article-title":"Long-term efficacy of zoledronic acid compared with risedronate in Paget's disease.","volume":"24","author":"Reid","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071617571706800_B16","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617571706800_B17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/11\/3367\/9087244\/jcem3367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/11\/3367\/9087244\/jcem3367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:43:11Z","timestamp":1594942991000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/96\/11\/3367\/2834357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,1]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2011-0412","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13086956.14743088","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.13086956.14412054","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,1]]}}}